Herborium's Group First Quarter Sales Grows 21% Over the Same Period of 2015
9th Consecutive Quarter of Double Digit Sales Growth
Herborium Group, Inc.
7 minutes ago
GlobeNewswire
Fort Lee, New Jersey, USA, March 31, 2015 (GLOBE NEWSWIRE) -- Herborium(R) Group,Inc.(OTC Pink: HBRM), www.Herborium.com, aBotanical Therapeutics(R) Company and the provider of uniqueall botanical medicinal products (Botanical Therapeutics(R)) thattarget dermatological problems such as acne, and other major healthand wellness concerns reports that its sales for the First Quarterof 2015 grew by 21% in comparison to the same period of 2014. Thissales growth places the present run rate for AcnEase(R) sales for2015 to approach $1,000,000.
This Quarter is also the 9th consecutive quarter ofdouble digit sales growth for Herborium Group, and 5thconsecutive quarter with an increase in the average value of theunit sales per customer. We attribute this increase to asignificant expansion in the Company's international salesespecially in the UK and France. The value of an averageinternational order is about 20% higher in comparison to a domesticorder, and also has a higher margin.
Herborium launched an independent French platform www.acnease.fr in February 2015 andthe initial sales on this platform has exceeded expectations. .
Mobile versions of www.acnease.com launched in2014 and a mobile version of www.acnease.fr alsogrowing and presently account for about 25% of Internet orders. In2014, "mobile" orders accounted for approximately 18 % of Internetorders
First Quarter of 2015 has also shown an increase indistributor's participation in revenues growing by 20% incomparison to the same period of 2014. This is a testament of agrowing wholesale market interest for Herborium's products.
The steady growth in revenues, and otherfinancial indicators such as market share, gross margin andexpending distribution channels put the Company closer to executingthe development plan and up listing plan announced for2015.
About Herborium Group,Inc.
Herborium Group, Inc., a botanical therapeutics(R) company thatdevelops, license and markets proprietary, botanical basedmedicinal products to consumers and healthcare professionals. TheCompany business model focuses on emerging market opportunitiesspearheaded by the growth of a new market sector located betweenhigh-cost, high-risk, ethical pharmaceuticals and commoditizedclassic nutraceuticals (supplements). The Company usesclinical validation and a proactive regulatory strategy based onthe FDA Guidance for Industry: Botanical Drug Products(FDA Guidance 2004) to establish and maintain adifferential advantage. Herborium has secured a pipeline ofbotanical ingredients based products in the areas of dermatologicalneeds, wellness and energy, prostate health, women's health andselected sexual disorders resulting from cardiovascular disease,use of anti-depressants, diabetes, surgical procedures, and otherproblems. Herborium Group sells its products in the United States,Canada, the United Kingdom, and continental Europe as well as inAustralia through a network of distributors, specialty retailers,and e-commerce. For more information, please visit www.herborium.com,www.acnease.com and www.acnease.fr
Safe Harbor Statement: This release containsforward-looking statements with respect to the results ofoperations and business of Herborium Group, Inc., which involvesrisks and uncertainties. The Company's actual future resultscould materially differ from those discussed. TheCompany intends that such statements about the Company's futureexpectations, including future revenues and earnings, and all otherforward looking statements be subject to the "Safe Harbors"provision of the Private Securities Litigation Reform Act of1995.
Contact:
Herborium Group, Inc.
Email: InvestorsRelations@Herborium.com
